Published in final edited form as:

Cancer. 2010 October 15; 116(20): 4882–4891. doi:10.1002/cncr.25454.

Trends in Incidence and Survival of Pediatric and Adolescent Germ Cell Tumors in the United States, 1975-2006

Jenny N. Poynter, Ph.D.^{1,2}, James F. Amatruda, M.D., Ph.D.³, and Julie A. Ross, Ph.D.^{1,2}

¹Division of Pediatric Epidemiology and Clinical Research, Department of Pediatrics, University of Minnesota, Minneapolis, MN, 55455

²Masonic Cancer Center, University of Minnesota

³Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, 75390

Abstract

Background—Pediatric germ cell tumors (GCTs) are rare and heterogeneous tumors with uncertain etiology. We used data from the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) Program to evaluate trends in incidence and survival of GCTs in boys and girls 19 years of age. Few studies have evaluated trends in pediatric GCTs. Results from these analyses may provide clues to the etiology of GCTs.

Methods—Frequencies, incidence rates and five-year relative survival rates stratified by sex were evaluated overall and for demographic subgroups based on age (0-9 and 10-19 years), race (white, black, and other), and ethnicity (non-Hispanic and Hispanic) as sample size permitted.

Results—In whites, the incidence of GCTs was lower for females than males in the 10-19 year age group (RR=0.47, 95% CI 0.42–0.53) while the rates were similar in the 0-9 year age group. In contrast, incidence rates were higher in black females than in black males in both age groups (RR=2.01, 95% CI 1.08–3.84 in 0-9 year olds; RR=3.30, 95% CI 2.13–5.28 in 10-19 year olds). The incidence of ovarian GCT was significantly higher in Hispanic than non-Hispanic girls in the 10–19 year age group. Incidence rates increased during the study period in boys ages 10-19 (APC 1.2, 95% CI 0.4–2.1) and girls ages 0-9 (APC 1.9, 95% CI 0.3-2.5).

Conclusions—The incidence of pediatric GCTs in the United States is increasing only in certain subgroups, suggesting that the etiology is not completely overlapping in all age groups. Differences in incidence patterns by race and ethnicity merit further investigation.

Keywords

pediatric cancer; germ cell tumors; SEER; incidence

Introduction

Pediatric GCTs are rare and heterogeneous tumors hypothesized to occur as a result of events *in utero*^{1, 2}, although the etiology is largely unknown. GCTs are grouped together due to their presumed common cell of origin, the primordial germ cell (PGC). During normal fetal development, PGCs originate in the embryonic yolk sac and then migrate to the gonads³. GCTs typically occur in the testes or ovaries; however, extragonadal GCTs can

Correspondence to: Jenny N. Poynter, Ph.D., Division of Pediatric Epidemiology and Clinical Research, University of Minnesota, 420 Delaware St SE MMC 715, Minneapolis, MN 55455. poynt006@umn.edu; phone: 612-625-4232; fax: 612-624-7147..

The authors have no financial disclosures.

occur and have been hypothesized to result from abnormal germ cell migration during development⁴. GCTs are grouped into two broad classes including seminomas, comprised of the seminomas of the testes and dysgerminomas of the ovaries, and nonseminomas, comprised of yolk sac tumors, teratomas, embryonal carcinomas, and choriocarcinomas⁵. Teratomas are composed of tissues from all three germ layers (ectoderm, mesoderm and endoderm) and are the most common GCT in the ovary and extragonadal locations. Yolk sac tumors (endodermal sinus tumors) are the most common malignant GCT in the testes of infants and young boys⁵.

The increasing incidence of testicular cancer in adults has been well documented⁶⁻¹². This increase is thought to be the result of a birth cohort effect, which supports a role for prenatal exposures in the etiology of this malignancy^{6, 10, 11}. In contrast, no clear trend in incidence has been observed in studies of pediatric testicular GCT, with several studies suggesting an increase in incidence^{9, 12, 13} while others have observed no significant change in incidence¹⁴⁻¹⁶. Survival is favorable for boys with GCTs¹⁷, which can be attributed to the effectiveness of platinum based chemotherapy in these tumors¹⁸⁻²⁰.

Trends in incidence of GCTs in girls have not been studied extensively. Several recent analyses using data from the NCI's Surveillance, Epidemiology and End Results (SEER) Program²¹ have evaluated ovarian GCTs in both the pediatric and adult populations²²⁻²⁵. These data suggest that the incidence of ovarian GCTs has not changed significantly²². Similar to testicular GCTs, the survival rate is very high for ovarian GCTs²²⁻²⁴.

In recent publications from our group^{17, 26}, we reported on incidence (1992-2004) and five year survival trends (1975-1999) for pediatric cancers, including GCTs overall, using data from the SEER Program²¹. In this analysis, we have evaluated GCTs in considerably more detail in a larger dataset with longer follow-up (1975-2006). Specifically, we have evaluated frequencies, incidence and survival by *tumor location* and *histology*, which may provide clues to the etiology of these tumors.

Methods

Using data from the NCI's SEER Program²¹, we analyzed incidence and survival of pediatric and adolescent GCTs in boys and girls, overall and by tumor location and histologic subtype as previously described^{17, 26}. We used data from the SEER 9 registries, which actively collects information on demographics, tumor site and morphology, stage at diagnosis, and vital status from nine cancer registries in five states (Connecticut, Hawaii, Iowa, New Mexico, and Utah) and four metropolitan areas (Atlanta, Detroit, San Francisco-Oakland, and Seattle-Puget Sound)²⁷. The SEER 9 registries represent ~9% of the U.S. population²⁷ with an estimated case ascertainment rate of 98%²⁸. We included first malignancies diagnosed from 1975—2006 among individuals 19 years of age. Moreover, data from the SEER 13 registries (SEER 9 registries plus Los Angeles, San Jose-Monterey, Rural Georgia and the Alaskan Native Tumor Registry) were used to evaluate incidence and survival by ethnicity (non-Hispanic vs. Hispanic).

International Classification of Disease for Oncology, 3rd edition (ICD-O-3)²⁹ histology and topology codes included in the International Classification of Childhood Cancer (ICCC), 3rd Edition³⁰ categories Xb. (malignant extracranial and extragonadal GCTs) and Xc. (malignant gonadal GCTs) were used to classify GCTs. In this analysis, we included only GCTs coded as malignant in the SEER database. For analyses by tumor location, we stratified the tumors into gonadal (topography codes C56.9, C62.0-C62.9) and extragonadal (C00.0-C55.9, C57.0-C61.9, C63.0-C69.9, C73.9-C75.0, C75.4-C76.8, C80.9). The following histology categories were evaluated: germinoma (ICCC 9060-9065), malignant

teratoma (9080-9084), embryonal carcinoma (9070-9072), yolk sac tumor (9071), choriocarcinoma (9100, 9103, 9104), and mixed GCT (9085, 9101, 9102, 9105).

This analysis used existing data with no personal identifiers; therefore, the study was exempt from review by the University of Minnesota Institutional Review Board.

Statistical Analysis

Frequencies and age-adjusted incidence rates were calculated using SEER*STAT software³¹; incidence rates are reported as the number of cases per 1,000,000 person-years of follow-up. The U.S. 2000 standard population was used in direct age standardization. Rate ratios (RR) were used to compare incidence rates in demographic subgroups. Trends in incidence rates were evaluated using the weighted least-squares regression in Joinpoint^{32, 33}. The average annual percentage changes (APC) and corresponding 95% confidence intervals (CIs) were calculated using calendar year as the independent variable and the natural logarithm of the age-adjusted incidence rate as the dependent variable. Joinpoints, which are points in time where a trend changes, were not permitted. The APC was considered significant if the confidence interval did not include 0.

The life tables method in SEER*Stat^{31, 34} was used to calculate five-year relative survival rates and corresponding standard errors for five 5-year diagnostic cohorts (1976-1980, 1981-1985, 1986-1990, 1991-1995, 1996-2000). SEER follow-up rates into 2006 were high for both males and females aged 0-19 years (94% and 93%, respectively)²⁷. Relative survival rates are ratios of observed-to-expected survival and are reported as percentages. The expected rates were based on data from the National Center for Health Statistics and take into account differences in distributions of age, sex, race, and year of diagnosis. Relative rates were adjusted if they exceeded 100%, increased over time, or involved heterogeneity in withdrawal (exact method). We used Z tests to compare relative survival rates across cohorts³⁵.

All analyses were stratified by sex. Incidence and survival were evaluated for the entire cohort and for demographic subgroups based on age (0-9 and 10-19 years), race (white, black, and other [includes American Indian/Alaskan Native, Asian/Pacific Islander]), and ethnicity (non-Hispanic and Hispanic) as sample size permitted.

Results

Incidence

Malignant GCTs were recorded in the SEER registry in 1,140 boys and 970 girls from 1975—2006. Incidence peaks were observed before age 1 year and from age 15—19 years in both boys and girls (Figure 1). Gonadal and extragonadal tumors were equally represented in boys diagnosed prior to age 4 years while the majority of tumors diagnosed after age 10 years were located in the testes (Figure 1A). In girls, the tumors diagnosed before age 4 years were comprised almost exclusively of extragonadal tumors while the majority of tumors diagnosed after age 10 years were mainly located in the ovaries (Figure 1B).

In infants and young children, teratomas and yolk sac tumors were the most common tumor type in both boys and girls (data not shown). Tumors with non-seminoma histology (teratoma, embryonal carcinoma and mixed GCTs) were the most common histologic subtypes in boys diagnosed after the age of 10 years. Germinomas and teratomas were the most common tumor types in adolescent girls.

There were no statistically significant differences in incidence of GCTs overall in boys or girls diagnosed before age 10 years by race; however, differences were observed by tumor

location (Table 1). The incidence of gonadal tumors was higher in boys in the other race category than in white boys ages 0-9 years (RR=2.16, 95% CI 1.31—3.44). In adolescent boys, the incidence was highest for whites and lowest for blacks, overall and for gonadal GCTs (Table 1). This difference was noted for most histologic subtypes as well. In contrast, for adolescent girls, the incidence was significantly higher in blacks than in whites for GCTs overall. The incidence of gonadal GCTs was significantly higher in girls in the other race category than in whites (RR=1.48, 95% CI 1.10—1.95), and the incidence of extragonadal GCTs was significantly higher in blacks than in whites (RR=2.44, 95% CI 1.41—4.08). The incidence of teratomas was significantly higher in both blacks and the other race category than whites for girls in this age category (RR=1.57, 95% CI 1.03—2.44 and RR=1.68, 95% CI 1.03—2.68, respectively).

Differences were also observed in the ratio of incidence in males and females in different racial groups. In whites, the incidence of GCTs was lower for females than males in the 10-19 year age group (RR=0.47, 95% CI 0.42—0.53) while incidence was similar in the 0-9 year age group (RR=1.01, 95% CI 0.80—1.29). In contrast, incidence rates were higher in black females than in black males in both age groups (RR=2.01, 95% CI 1.08—3.84 in 0-9 year olds; RR=3.30, 95% CI 2.13—5.28 in 10-19 year olds). In the “other” race category, no significant differences in incidence were observed by sex in either age group (RR=0.56, 95% CI 0.28—1.08 for 0-9 year olds; RR=1.11, 95% CI 0.76—1.61 for 10-19 year olds).

There were no significant differences in incidence of GCTs overall, by tumor location, or by tumor histology in non-Hispanic vs. Hispanic boys and girls ages 0—9 years. Similarly, no significant differences in incidence were observed by ethnicity in 10-19 year old boys, overall or by tumor location (Table 1). We did observe a higher incidence of mixed GCTs in Hispanic boys than in non-Hispanic boys in this age group (RR=1.39, 95% CI 1.09—1.76). The incidence of GCTs overall was higher in 10—19 year old girls with Hispanic ethnicity, and this difference was due to the increased incidence of gonadal GCTs in this subgroup (RR=1.39, 95% CI 1.10—1.75).

Incidence Trends

Trends in incidence of GCTs during the period 1975-2006 are shown in Figure 2. There was no evidence for an increase in incidence of GCTs in boys ages 0-9 years (APC -0.3, 95% CI -1.9-1.5). In contrast, we observed a statistically significant increase in incidence during the study period in boys ages 10-19 years (APC 1.2, 95% CI 0.4—2.1). In girls, the data suggest that incidence of GCTs increased in ages 0-9 years (APC 1.9, 95% CI 0.3-2.5) while no increase was seen in ages 10-19 years (APC -0.1, 95% CI -0.8-0.7). These findings should be interpreted with caution because all subgroups included <10 cases in several years. The small sample size did not permit evaluation of incidence trends by tumor location, tumor histology or race/ethnicity.

Survival Rates

Five-year relative survival rates for GCTs overall were high in all age groups. For example, in the diagnostic period 1996-2000, 5-year relative survival was 94.1 (95% CI 75.8-98.7) in boys ages 0-9 years, 94.5 (95% CI 89.0-97.2) in boys ages 10-19 years, 89.3 (95% CI 69.2-96.6) in girls ages 0-9 years, and 97.7 (95% CI 90.5-99.5) in girls ages 10-19 years. Five-year relative survival rates differed by tumor location with more favorable survival for gonadal tumors than for extragonadal tumors (Figure 3). Significant improvements in survival from gonadal GCTs were observed in all diagnostic periods compared with the 1976—1980 diagnostic period in boys ages 10-19 years, and survival was higher for extragonadal tumors in this age group for 1996—2000 compared with 1976—1980 and 1986—1990. For females, survival improved significantly for the 1996—2000 period

compared with 1976—1980. The difference in survival between gonadal and extragonadal tumors was more pronounced in boys than girls and decreased in more recent diagnostic periods. Survival was significantly higher for extragonadal tumors during the 1996—2000 diagnostic period compared with the 1976—1980 and the 1981—1985 periods in 0-9 year old boys ($p < 0.05$). Survival was especially poor for extragonadal tumors during the 1976—1980 diagnostic period in adolescent boys and girls, with marked improvement over time. The small sample size precludes analysis of survival by tumor histology and race/ethnicity.

Discussion

We have evaluated incidence and survival of pediatric and adolescent GCTs during the period of 1975-2006 using data from the SEER Program. This relatively large dataset has allowed us to evaluate incidence overall in boys and girls, and also for subgroups based on tumor location and histology. No significant differences in incidence rates by race or ethnicity were observed in children diagnosed between ages 0-9 years; however, statistically significant differences were observed in the older age group. Moreover, incidence rates increased significantly during the study period for boys in the 10-19 year age group and girls in the 0-9 year age group.

The distribution of tumors by location differed in the pediatric and adolescent age groups, with extragonadal tumors comprising a larger percentage of tumors diagnosed in children before the age of 4 years than children diagnosed after age 10 years. Previous reports have estimated that 40-55% of pediatric GCTs are found in extragonadal locations³⁶⁻⁴⁰ while only 5-10% of GCTs in adults are found in extragonadal locations^{3, 41}. This difference is hypothesized to be due to differences in the maturity of the germ cells that give rise to the tumors in these age groups⁴. Pediatric GCTs likely originate from a PGC that underwent immediate reprogramming to become a pluripotent embryonic germ cell, while GCTs in adolescents and young adults most likely originate from more mature PGCs⁴², which may be unable to survive outside of the normal niches of the ovary and testis or specialized sites such as the thymus, in the case of mediastinal GCTs.

The incidence of GCTs was similar in boys and girls in the 0-9 year age group while the incidence was much higher in boys in the 10-19 year age group. This is thought to be due to the more limited number of germ cells in females in the mature ovaries^{43, 44}. Incidence patterns differed by tumor location in boys and girls. Several factors may contribute to these differences. The higher rate of gonadal GCTs in young boys may reflect a more permissive environment in the immature testis than in the immature ovary. Another factor may be physiologic differences between the sexes: in females, germ cells undergo a prenatal meiotic arrest that persists until puberty, whereas in males, mitotic proliferation of germ cells resumes shortly after birth and continues throughout childhood⁴⁵. Yet another factor may be the lower number of germ cells in young girls, owing to apoptosis of germ cells during development. In this context, it is particularly interesting that when germ cell apoptosis is inhibited in a mouse model, a population of ectopic germ cells with delayed maturation can be identified in the sacral/tail region specifically in female mice⁴⁶. If a similar phenomenon occurs in humans, it may be that germ cells escaping developmental apoptosis go on to form sacrococcygeal tumors, particularly in girls.

The increase in incidence of testicular GCTs in young adults during the past half century has been well documented in the literature⁶⁻¹². These data from the SEER Program support other reports that GCTs are increasing in adolescent males; however, there is no corresponding increase in incidence in the younger pediatric male age group. In contrast, we observed increasing incidence of GCTs in girls in the pediatric age group (0-9 years) but no

corresponding increase in adolescent girls (10-19 years). These data suggest that differing etiologic factors are involved in GCTs in different age groups and by sex.

Evidence suggests that at least some risk factors, such as cryptorchidism^{47, 48}, overlap for pediatric and adult testicular GCTs; however, the distinct clinical^{3, 19, 49, 50} and genetic profiles⁵¹⁻⁵³ of pediatric and adult GCTs provide support for distinct etiologies. Several mechanisms have been hypothesized for the increase in testicular GCTs in males, with much attention focused on exposure to estrogens and environmental hormone disruptors⁵⁴; however, the exact mechanism is not clear. Epidemiologic studies have evaluated the role of *in utero* hormone exposure in both adult TGCT^{1, 2, 55, 56} and in pediatric GCTs^{40, 57, 58}, with conflicting results. Endocrine disrupting agents, including persistent organochlorine pesticides (POP)⁵⁹⁻⁶¹ and polychlorinated biphenyls^{59, 62} have also been investigated in epidemiologic studies of adult TGCT, with evidence suggesting that POPs⁶⁰ may be associated with increased risk. Data from *in vitro* and *in vivo* studies provides evidence that exposure to estrogens and endocrine disruptors may influence germ cell apoptosis⁶³⁻⁶⁶ and stimulate cell proliferation^{67, 68}. Exposure to these chemicals has increased over time and could be responsible for the observed increase in incidence. Further investigation will be required to draw definitive conclusions on the role of these agents in risk of GCTs, especially in girls.

We observed different patterns of GCT incidence by race and ethnicity in males and females. In the adolescent age group, the incidence was significantly higher in white males than in males in the other race groups. This higher incidence of testicular GCT in adult white males has been well-documented in the literature^{10, 69, 70}. In contrast, incidence rates were significantly lower in white females in the adolescent age category compared with females in the other race categories. In addition, higher incidence of gonadal GCTs was observed in Hispanic females in the 10-19 year age group. Previous studies have also reported differences in GCT incidence by race and ethnicity. A recent study of Southeast Asian Children in California reported a higher incidence of GCTs in Asians compared with non-Hispanic whites⁷¹. Previous reports have reported a higher incidence of GCTs in Hispanic children in the United States⁷²⁻⁷⁴, and one of these studies found that the increased incidence was confined mainly to gonadal GCTs and reached statistical significance only in females⁷⁴. Any explanations for these differing incidence patterns would be purely speculative; however, it is possible that genetic factors or differences in hormone levels may play a role.

Five-year relative survival rates are very high for pediatric GCTs, mainly due to the effectiveness of platinum-based chemotherapy¹⁸⁻²⁰. While survival rates were high overall, differences were observed in survival rates by tumor location, with more favorable survival in tumors located in the gonads than in extragonadal locations. This finding is supported by numerous publications showing lower survival rates in pediatric GCTs in extragonadal locations^{38, 75, 76}. Differing survival rates based on extragonadal location have also been reported^{38, 77}, unfortunately the number of cases in this analysis was not sufficient to stratify by extragonadal location. The higher survival rate in gonadal than extragonadal tumors has been hypothesized to be due to more complete tumor excision in tumors located in the gonads¹⁹. Other potential explanations for the higher survival rate for gonadal GCTs include differences in sensitivity to chemotherapy and induction of apoptosis.

The SEER dataset has many strengths, including a high rate of case ascertainment and high quality data. However; several limitations must also be considered. The SEER 9 registries provide population-based ascertainment of cancer cases for approximately 9% of the US population. Differences in demographic characteristics⁷⁸ and cancer incidence rates⁷⁹ may exist in the 91% of the population not covered by the SEER 9 registries. Teratomas in

children are frequently considered benign, and misreporting of these tumors is a possibility. Clinical and diagnostic practices have changed during the long time period of case ascertainment for this analysis (1975–2006), which may have influenced our results. Improved imaging and diagnosis would most likely lead to an increasing incidence over time. Since we observed increasing incidence rates in some subgroups, this is unlikely to completely explain the increases observed here. The large number of tests we have conducted leads to the possibility that some findings may be due to chance. The small numbers in some analyses, particularly for analyses of tumor histology, is also a limitation of this analysis as unstable estimates caused by small cells could lead to spurious findings.

In summary, this analysis of the SEER data suggests that the incidence of GCTs may be increasing in young girls (0–9 years) in addition to the well-documented increase in adolescent males (10–19 years). This analysis also highlights differences in incidence patterns in racial and ethnic subgroups. These findings should be explored further as they may shed light on the etiology of this poorly understood group of tumors.

Acknowledgments

Research support: This research was supported by the Children's Cancer Research Fund, Minneapolis, MN

References

1. Henderson BE, Benton B, Jing J, Yu MC, Pike MC. Risk factors for cancer of the testis in young men. *Int J Cancer*. May 15; 1979 23(5):598–602. [PubMed: 37169]
2. Schottenfeld D, Warshauer ME, Sherlock S, Zauber AG, Leder M, Payne R. The epidemiology of testicular cancer in young adults. *Am J Epidemiol*. Aug; 1980 112(2):232–246. [PubMed: 6106385]
3. Rescorla FJ, Breitfeld PP. Pediatric germ cell tumors. *Curr Probl Cancer*. Nov-Dec; 1999 23(6):257–303. [PubMed: 10614561]
4. Oosterhuis JW, Stoop H, Honecker F, Looijenga LH. Why human extragonadal germ cell tumours occur in the midline of the body: old concepts, new perspectives. *Int J Androl*. Aug; 2007 30(4): 256–263. discussion 263–254. [PubMed: 17705807]
5. Cushing, B.; Perlman, EJ.; Marina, NM.; Castleberry, RP. Germ Cell Tumors. In: Pizzo, P.; Poplack, D., editors. *Principles and practice of pediatric oncology*. 5th ed. Lippincott, Williams and Wilkins; Philadelphia, PA: 2006.
6. Bergstrom R, Adami HO, Mohnen M, et al. Increase in testicular cancer incidence in six European countries: a birth cohort phenomenon. *J Natl Cancer Inst*. Jun 5; 1996 88(11):727–733. [PubMed: 8637026]
7. Weir HK, Marrett LD, Moravan V. Trends in the incidence of testicular germ cell cancer in Ontario by histologic subgroup, 1964–1996. *Cmaj*. Jan 26; 1999 160(2):201–205. [PubMed: 9951441]
8. Liu S, Semenciw R, Waters C, Wen SW, Mery LS, Mao Y. Clues to the aetiological heterogeneity of testicular seminomas and non-seminomas: time trends and age-period-cohort effects. *Int J Epidemiol*. Oct; 2000 29(5):826–831. [PubMed: 11034964]
9. dos Santos Silva I, Swerdlow AJ, Stiller CA, Reid A. Incidence of testicular germ-cell malignancies in England and Wales: trends in children compared with adults. *Int J Cancer*. Nov 26; 1999 83(5): 630–634. [PubMed: 10521799]
10. McGlynn KA, Devesa SS, Sigurdson AJ, Brown LM, Tsao L, Tarone RE. Trends in the incidence of testicular germ cell tumors in the United States. *Cancer*. Jan 1; 2003 97(1):63–70. [PubMed: 12491506]
11. Richiardi L, Bellocco R, Adami HO, et al. Testicular cancer incidence in eight northern European countries: secular and recent trends. *Cancer Epidemiol Biomarkers Prev*. Dec; 2004 13(12):2157–2166. [PubMed: 15598775]
12. Lacerda HM, Akre O, Merletti F, Richiardi L. Time trends in the incidence of testicular cancer in childhood and young adulthood. *Cancer Epidemiol Biomarkers Prev*. Jul; 2009 18(7):2042–2045. [PubMed: 19531675]

13. Moller H, Jorgensen N, Forman D. Trends in incidence of testicular cancer in boys and adolescent men. *Int J Cancer*. Jun 9; 1995 61(6):761–764. [PubMed: 7790108]
14. Swerdlow AJ, Stiller CA, Wilson LM. Prenatal factors in the aetiology of testicular cancer: an epidemiological study of childhood testicular cancer deaths in Great Britain, 1953-73. *J Epidemiol Community Health*. Jun; 1982 36(2):96–101. [PubMed: 7119662]
15. Walsh TJ, Grady RW, Porter MP, Lin DW, Weiss NS. Incidence of testicular germ cell cancers in U.S. children: SEER program experience 1973 to 2000. *Urology*. Aug; 2006 68(2):402–405. discussion 405. [PubMed: 16904461]
16. Alanee S, Shukla A. Paediatric testicular cancer: an updated review of incidence and conditional survival from the Surveillance, Epidemiology and End Results database. *BJU Int*. Apr 17.2009
17. Linabery AM, Ross JA. Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975-1999. *Cancer*. Nov 1; 2008 113(9):2575–2596. [PubMed: 18837040]
18. Mann JR, Raafat F, Robinson K, et al. The United Kingdom Children's Cancer Study Group's second germ cell tumor study: carboplatin, etoposide, and bleomycin are effective treatment for children with malignant extracranial germ cell tumors, with acceptable toxicity. *J Clin Oncol*. Nov 15; 2000 18(22):3809–3818. [PubMed: 11078494]
19. Gobel U, Schneider DT, Calaminus G, Haas RJ, Schmidt P, Harms D. Germ-cell tumors in childhood and adolescence. GPOH MAKEI and the MAHO study groups. *Ann Oncol*. Mar; 2000 11(3):263–271. [PubMed: 10811491]
20. Cushing B, Giller R, Cullen JW, et al. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882. *J Clin Oncol*. Jul 1; 2004 22(13):2691–2700. [PubMed: 15226336]
21. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER 9 Regs Limited-Use, Nov 2008 Sub (1973-2006). National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; Bethesda, Md: released April 2009, based on the November 2008 submission. Available from: <http://www.seer.cancer.gov>
22. Smith HO, Berwick M, Verschraegen CF, et al. Incidence and survival rates for female malignant germ cell tumors. *Obstet Gynecol*. May; 2006 107(5):1075–1085. [PubMed: 16648414]
23. Kumar S, Shah JP, Bryant CS, et al. The prevalence and prognostic impact of lymph node metastasis in malignant germ cell tumors of the ovary. *Gynecol Oncol*. Aug; 2008 110(2):125–132. [PubMed: 18571705]
24. Brookfield KF, Cheung MC, Koniaris LG, Sola JE, Fischer AC. A population-based analysis of 1037 malignant ovarian tumors in the pediatric population. *J Surg Res*. Sep; 2009 156(1):45–49. [PubMed: 19592022]
25. Bryant CS, Kumar S, Shah JP, et al. Racial disparities in survival among patients with germ cell tumors of the ovary--United States. *Gynecol Oncol*. Sep; 2009 114(3):437–441. [PubMed: 19560191]
26. Linabery AM, Ross JA. Trends in childhood cancer incidence in the U.S. (1992-2004). *Cancer*. Jan 15; 2008 112(2):416–432. [PubMed: 18074355]
27. Horner, MJRL.; Krapcho, M.; Neyman, N.; Aminou, R.; Howlader, N.; Altekruse, SF.; Feuer, EJ.; Huang, L.; Mariotto, A.; Miller, BA.; Lewis, DR.; Eisner, MP.; Stinchcomb, DG.; Edwards, BK., editors. SEER Cancer Statistics Review, 1975-2006. National Cancer Institute; Bethesda, MD: 2009. based on November 2008 SEER data submission, posted to the SEER web site Available from: http://seer.cancer.gov/csr/1975_2006/
28. Zippin C, Lum D, Hankey BF. Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. *Cancer*. Dec 1; 1995 76(11):2343–2350. [PubMed: 8635041]
29. World Health Organization. International Classification of Diseases for Oncology. 3rd ed. WHO; Geneva: 2000.
30. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, third edition. *Cancer*. Apr 1; 2005 103(7):1457–1467. [PubMed: 15712273]

31. Surveillance Research Program. SEER*Stat software Version 6.5.2. National Cancer Institute; Available from: www.seer.cancer.gov/seerstat
32. National Cancer Institute. Joinpoint Regression Program Version 3.3.1. Statistical Research and Applications Branch, National Cancer Institute; Bethesda, MD: Apr. 2005
33. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for joinpoint regression with applications to cancer rates. *Stat Med.* Feb 15; 2000 19(3):335–351. [PubMed: 10649300]
34. Ederer F, Axtell LM, Cutler SJ. The relative survival rate: a statistical methodology. *Natl Cancer Inst Monogr.* Sep.1961 6:101–121. [PubMed: 13889176]
35. Brown CC. The statistical comparison of relative survival rates. *Biometrics.* Dec; 1983 39(4):941–948. [PubMed: 6671129]
36. Harms D, Janig U. Germ cell tumours of childhood. Report of 170 cases including 59 pure and partial yolk-sac tumours. *Virchows Arch A Pathol Anat Histopathol.* 1986; 409(2):223–239. [PubMed: 2424170]
37. Bernstein L, Smith MA, Liu L, Deapen D, Friedman DL. Germ cell, trophoblastic, and other gonadal neoplasms. National Cancer Institute, SEER Pediatric Monograph. 1999:125–137.
38. De Backer A, Madern GC, Pieters R, et al. Influence of tumor site and histology on long-term survival in 193 children with extracranial germ cell tumors. *Eur J Pediatr Surg.* Feb; 2008 18(1):1–6. [PubMed: 18302061]
39. Chen Z, Robison L, Giller R, et al. Risk of childhood germ cell tumors in association with parental smoking and drinking. *Cancer.* Mar 1; 2005 103(5):1064–1071. [PubMed: 15685619]
40. Shu XO, Nesbit ME, Buckley JD, Krailo MD, Robinson LL. An exploratory analysis of risk factors for childhood malignant germ-cell tumors: report from the Childrens Cancer Group (Canada, United States). *Cancer Causes Control.* May; 1995 6(3):187–198. [PubMed: 7612798]
41. Houldsworth J, Korkola JE, Bosl GJ, Chaganti RS. Biology and genetics of adult male germ cell tumors. *J Clin Oncol.* Dec 10; 2006 24(35):5512–5518. [PubMed: 17158536]
42. Oosterhuis JW, Looijenga LH. Testicular germ-cell tumours in a broader perspective. *Nat Rev Cancer.* Mar; 2005 5(3):210–222. [PubMed: 15738984]
43. Motta PM, Nottola SA, Makabe S. Natural history of the female germ cell from its origin to full maturation through prenatal ovarian development. *Eur J Obstet Gynecol Reprod Biol.* Dec; 1997 75(1):5–10. [PubMed: 9447340]
44. Moller H, Evans H. Epidemiology of gonadal germ cell cancer in males and females. *Apmis.* Jan; 2003 111(1):43–46. discussion 46–48. [PubMed: 12752232]
45. Wilhelm D, Palmer S, Koopman P. Sex determination and gonadal development in mammals. *Physiol Rev.* Jan; 2007 87(1):1–28. [PubMed: 17237341]
46. Runyan C, Gu Y, Shoemaker A, Looijenga L, Wylie C. The distribution and behavior of extragonadal primordial germ cells in Bax mutant mice suggest a novel origin for sacrococcygeal germ cell tumors. *Int J Dev Biol.* 2008; 52(4):333–344. [PubMed: 18415933]
47. Johnson KJ, Ross JA, Poynter JN, Linabery AM, Robison LL, Shu XO. Paediatric germ cell tumours and congenital abnormalities: a Children's Oncology Group study. *Br J Cancer.* Aug 4; 2009 101(3):518–521. [PubMed: 19603020]
48. Sarma, A.; McLaughlin, J.; Schottenfeld, D. Testicular Cancer. In: Schottenfeld, D.; Fraumeni, JE., Jr., editors. *Cancer epidemiology and prevention.* 3rd ed. Oxford University Press; New York: 2006. p. 1159–1160.
49. Marina NM, Cushing B, Giller R, et al. Complete surgical excision is effective treatment for children with immature teratomas with or without malignant elements: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study. *J Clin Oncol.* Jul; 1999 17(7):2137–2143. [PubMed: 10561269]
50. Baranzelli MC, Kramar A, Bouffet E, et al. Prognostic factors in children with localized malignant nonseminomatous germ cell tumors. *J Clin Oncol.* Apr.1999 17(4):1212. [PubMed: 10561181]
51. Perlman EJ, Cushing B, Hawkins E, Griffin CA. Cytogenetic analysis of childhood endodermal sinus tumors: a Pediatric Oncology Group study. *Pediatr Pathol.* Jul-Aug;1994 14(4):695–708. [PubMed: 7971587]

52. Bussey KJ, Lawce HJ, Olson SB, et al. Chromosome abnormalities of eighty-one pediatric germ cell tumors: sex-, age-, site-, and histopathology-related differences--a Children's Cancer Group study. *Genes Chromosomes Cancer*. Jun; 1999 25(2):134–146. [PubMed: 10337997]
53. Bussey KJ, Lawce HJ, Himoe E, et al. Chromosomes 1 and 12 abnormalities in pediatric germ cell tumors by interphase fluorescence in situ hybridization. *Cancer Genet Cytogenet*. Mar; 2001 125(2):112–118. [PubMed: 11369053]
54. Skakkebaek NE, Rajpert-De Meyts E, Jorgensen N, et al. Germ cell cancer and disorders of spermatogenesis: an environmental connection? *Apmis*. Jan; 1998 106(1):3–11. discussion 12. [PubMed: 9524557]
55. Depue RH, Pike MC, Henderson BE. Estrogen exposure during gestation and risk of testicular cancer. *J Natl Cancer Inst*. Dec; 1983 71(6):1151–1155. [PubMed: 6140323]
56. Weir HK, Marrett LD, Kreiger N, Darlington GA, Sugar L. Pre-natal and peri-natal exposures and risk of testicular germ-cell cancer. *Int J Cancer*. Aug 1; 2000 87(3):438–443. [PubMed: 10897052]
57. Walker AH, Ross RK, Haile RW, Henderson BE. Hormonal factors and risk of ovarian germ cell cancer in young women. *Br J Cancer*. Apr; 1988 57(4):418–422. [PubMed: 3390378]
58. Shankar S, Davies S, Giller R, et al. In utero exposure to female hormones and germ cell tumors in children. *Cancer*. Jan 18; 2006 106(5):1169–1177. [PubMed: 16421921]
59. Hardell L, van Bavel B, Lindstrom G, et al. Increased concentrations of polychlorinated biphenyls, hexachlorobenzene, and chlordanes in mothers of men with testicular cancer. *Environ Health Perspect*. Jun; 2003 111(7):930–934. [PubMed: 12782494]
60. McGlynn KA, Quraishi SM, Graubard BI, Weber JP, Rubertone MV, Erickson RL. Persistent organochlorine pesticides and risk of testicular germ cell tumors. *J Natl Cancer Inst*. May 7; 2008 100(9):663–671. [PubMed: 18445826]
61. Biggs ML, Davis MD, Eaton DL, et al. Serum organochlorine pesticide residues and risk of testicular germ cell carcinoma: a population-based case-control study. *Cancer Epidemiol Biomarkers Prev*. Aug; 2008 17(8):2012–2018. [PubMed: 18708392]
62. McGlynn KA, Quraishi SM, Graubard BI, Weber JP, Rubertone MV, Erickson RL. Polychlorinated biphenyls and risk of testicular germ cell tumors. *Cancer Res*. Mar 1; 2009 69(5):1901–1909. [PubMed: 19223531]
63. Delbes G, Levacher C, Pairault C, et al. Estrogen receptor beta-mediated inhibition of male germ cell line development in mice by endogenous estrogens during perinatal life. *Endocrinology*. Jul; 2004 145(7):3395–3403. [PubMed: 15044378]
64. Chaki SP, Misro MM, Gautam DK, Kaushik M, Ghosh D, Chainy GB. Estradiol treatment induces testicular oxidative stress and germ cell apoptosis in rats. *Apoptosis*. Aug; 2006 11(8):1427–1437. [PubMed: 16830234]
65. Li YJ, Song TB, Cai YY, et al. Bisphenol A exposure induces apoptosis and upregulation of Fas/FasL and caspase-3 expression in the testes of mice. *Toxicol Sci*. Apr; 2009 108(2):427–436. [PubMed: 19193734]
66. Lambrot R, Muczynski V, Lecureuil C, et al. Phthalates impair germ cell development in the human fetal testis in vitro without change in testosterone production. *Environ Health Perspect*. Jan; 2009 117(1):32–37. [PubMed: 19165384]
67. Bouskine A, Nebout M, Mograbi B, Brucker-Davis F, Roger C, Fenichel P. Estrogens promote human testicular germ cell cancer through a membrane-mediated activation of extracellular regulated kinase and protein kinase A. *Endocrinology*. Feb; 2008 149(2):565–573. [PubMed: 18039775]
68. Bouskine A, Nebout M, Brucker-Davis F, Benahmed M, Fenichel P. Low doses of bisphenol A promote human seminoma cell proliferation by activating PKA and PKG via a membrane G-protein-coupled estrogen receptor. *Environ Health Perspect*. Jul; 2009 117(7):1053–1058. [PubMed: 19654912]
69. Shah MN, Devesa SS, Zhu K, McGlynn KA. Trends in testicular germ cell tumours by ethnic group in the United States. *Int J Androl*. Aug; 2007 30(4):206–213. discussion 213–204. [PubMed: 17708751]

70. Weir HK, Jim MA, Marrett LD, Fairley T. Cancer in American Indian and Alaska Native young adults (ages 20-44 years): US, 1999-2004. *Cancer*. Sep 1; 2008 113(5 Suppl):1153-1167. [PubMed: 18720386]
71. Ducore JM, Parikh-Patel A, Gold EB. Cancer occurrence in Southeast Asian children in California. *J Pediatr Hematol Oncol*. Oct; 2004 26(10):613-618. [PubMed: 15454830]
72. Howe HL, Wu X, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations. *Cancer*. Oct 15; 2006 107(8):1711-1742. [PubMed: 16958083]
73. Wilkinson JD, Gonzalez A, Wohler-Torres B, et al. Cancer incidence among Hispanic children in the United States. *Rev Panam Salud Publica*. Jul; 2005 18(1):5-13. [PubMed: 16105320]
74. Glazer ER, Perkins CI, Young JL Jr. Schlag RD, Campleman SL, Wright WE. Cancer among Hispanic children in California, 1988-1994: comparison with non-Hispanic white children. *Cancer*. Sep 15; 1999 86(6):1070-1079. [PubMed: 10491536]
75. Bethel CA, Mutabagani K, Hammond S, Besner GE, Caniano DA, Cooney DR. Nonteratomatous germ cell tumors in children. *J Pediatr Surg*. Jul; 1998 33(7):1122-1126. discussion 1126-1127. [PubMed: 9694107]
76. Shah JP, Kumar S, Bryant CS, et al. A population-based analysis of 788 cases of yolk sac tumors: A comparison of males and females. *Int J Cancer*. Dec 1; 2008 123(11):2671-2675. [PubMed: 18767035]
77. Marina N, London WB, Frazier AL, et al. Prognostic factors in children with extragonadal malignant germ cell tumors: a pediatric intergroup study. *J Clin Oncol*. Jun 1; 2006 24(16):2544-2548. [PubMed: 16735707]
78. SEER. Characteristics of the SEER population compared with the total United States population. National Cancer Institute; Available from: <http://seer.cancer.gov/registries/characteristics.html>
79. Merrill RM, Dearden KA. How representative are the surveillance, epidemiology, and end results (SEER) program cancer data of the United States? *Cancer Causes Control*. Dec; 2004 15(10):1027-1034. [PubMed: 15801487]

Figure 1.
Incidence of pediatric GCT by tumor location in boys and girls in the SEER registry, 1975—2006.

Figure 2.
Incidence trends in pediatric GCTs in boys and girls by age group (1975—2006).

Figure 3.
Five-year relative survival rates for boys and girls for 5-year diagnostic periods by age group and tumor location

Table 1

Frequency and incidence rates of pediatric germ cell tumors by race, ethnicity, and age group in girls and boys in the NCI Surveillance, Epidemiology and End Results Registry, overall and by tumor location

	Boys					Girls				
	Overall		Gonadal		Extragenadal	Overall		Gonadal		Extragenadal
	N ¹ (%)	Incidence Rate	N ¹ (%)	Incidence Rate	N ¹ (%)	Incidence Rate	N ¹ (%)	Incidence Rate	N ¹ (%)	Incidence Rate
Age Group: 0-9 years										
Race ⁴										
White	149 (76)	3.3	83 (73)	1.8	66 (81)	1.4	141 (75)	3.3	41 (84)	1.0
Black	17 (9)	2.1	7 (6)	0.9	10 (12)	1.2	33 (17)	4.2	5 (10)	0.6
American Indian/ Alaskan Native, Asian/Pacific Islander	29 (15)	4.8	24 (21)	4.02	5 (6)	0.8	15 (8)	2.7	3 (6)	0.6
Ethnicity ⁵										
Non-Hispanic	114 (67)	3.6	58 (62)	1.8	56 (73)	1.8	126 (74)	4.2	35 (66)	1.2
Hispanic	56 (33)	4.3	35 (38)	2.7	21 (27)	1.6	45 (26)	3.8	18 (34)	1.7
Age Group: 10-19 years										
Race ⁴										
White	853 (91)	18.6	787 (92)	17.1	66 (78)	1.4	384 (72)	8.8	331 (72)	7.6
Black	27 (3)	3.6 ²	23 (3)	3.1 ²	4 (5)	0.5 ²	89 (17)	11.8 ²	67 (15)	8.9
American Indian/ Alaskan Native, Asian/Pacific Islander	58 (6)	10.8 ²	43 (5)	7.8 ²	15 (18)	2.7	62 (12)	11.6	60 (13)	11.2 ²
Ethnicity ⁵										
Non-Hispanic	542 (72)	17.7	501 (72)	16.4	41 (73)	1.3	277 (69)	9.2	250 (70)	8.3
Hispanic	209 (28)	20.8	194 (28)	19.3	15 (27)	1.5	124 (31)	13.2 ³	109 (30)	11.5 ³

¹ Number of cases in SEER registry, 1975–2006

² Rate is significantly different than rate in white

- ³ Rate is significantly different than rate in non-Hispanic
- ⁴ Incidence data from the SEER 9 Registries, 1975-2006
- ⁵ Incidence data from the SEER 13 Registries, 1992-2006